---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-293893"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:22:13.997729+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mirum discontinues OHANA Phase 2b trial of volixibat in ICP due to enrollment feasibility

## Summary
- Discontinued Phase 2b OHANA trial of volixibat for intrahepatic cholestasis of pregnancy (ICP).
- Interim analysis showed meaningful reductions in serum bile acids and pruritus in treated patients.
- Decision driven by unique enrollment challenges in high-risk pregnancy setting.
- Company will prioritize other pipeline programs following the discontinuation.

## SEC filing metadata
- accession: 0001193125-22-293893
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/0001193125-22-293893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/d426142d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-293893
- JSON: https://secwatch.observer/filing/0001193125-22-293893.json
- Plain text: https://secwatch.observer/filing/0001193125-22-293893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.